Nov 28, 2012 ENGLER ROBERTDirector 15,000 Direct Purchase at $5.57 per share. 83,550
Nov 13, 2012 SHAFFER JAMES POfficer 20,000 Direct Purchase at $5.22 per share. 104,399
Nov 12, 2012 FALBERG KATHRYN EDirector 50,000 Direct Purchase at $5.21 per share. 260,500
Aug 26, 2012 KELLEY KENNETH JDirector 20,000 Direct Purchase at $5.70 per share. 114,000
Aug 12, 2012 FROST GREGORY IANOfficer 2,000 Direct Purchase at $5.50 per share. 11,000
Jun 4, 2012 KIRK RANDAL JDirector 5,463 Indirect Purchase at $7.48 per share. 40,863
Jun 3, 2012 KIRK RANDAL JDirector 89,646 Indirect Purchase at $7.37 per share. 660,691
May 31, 2012 KIRK RANDAL JDirector 99,080 Indirect Purchase at $7.39 per share. 732,201
May 16, 2012 KIRK RANDAL JDirector 299,007 Indirect Purchase at $7.50 per share. 2,242,552May 15, 2012 KIRK RANDAL JDirector 344,910 Indirect Purchase at $7.44 per share. 2,566,130
May 14, 2012 KIRK RANDAL JDirector 427,581 Indirect Purchase at $7.35 per share. 3,142,720
If Baker's Bought at $6.22 , They Believe Going To At least $12.50. They Don't Buy Unless They Think it Will At least Double.
Baker Fund Stocks Triple Easy. PCYC They Bought at $19 And Is $90 Now.
June 17, 2013 Baker Bros Advisors LLC PortfolioHALO Halozyme Therapeutics Inc 17 - $6.22 $18,346,000 3,182,251 0.48% 6,471,000 1,412,475 3.071 Biotechnology
Litigation Settlements, Data Compliance Reviews, and Clinical Trials Pave Way for Solid Footing in Healthcare - Research Report on Pfizer, Merck, Bristol-Myers Squibb, Keryx and Pacira Pharmaceuticals
PR Newswire Monday June 17, 2013
On June 3, 2013, Keryx Biopharmaceuticals, Inc. (Keryx) announced the presentation of updated efficacy and safety data from the Phase 3 long-term clinical trial of ZenerexZerenex (ferric citrate). Based on the efficacy results, Keryx determined that Zerenex is an efficacious and safe oral phosphate binder that controls serum phosphorus, increases iron stores as measured by serum ferritin and TSAT, and reduced the use of IV iron and ESAs, while sustaining hemoglobin as compared to the active control group. ZenerexZerenex met thepre-defined primary and key secondary endpoints for the treatment of elevated serum phosphorus levels, or hyperphosphatemia, in patients with end-stage renal disease (ESRD) on dialysis
bear raid tues.
this is a buying opportunity, traders who miss this will be very jealous.they missed it.
ACAD Website :
We believe that pimavanserin also has the potential to address a range of other neurological and psychiatric disorders that are under served by currently available anti psychotics and represent large unmet medical needs. This may include treatment for psychoses associated with other neurological disorders, including Alzheimer’s disease, and as a co-therapy for schizophrenia
take a hint going to $20's